Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-CMDR
- Development stage
- Phase 2
- Lead developer
- U.S. Military HIV Research Program
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
MVA-CMDR is a candidate HIV-1 vaccine based on a recombinant modified vaccinia Ankara (MVA) viral vector that expresses HIV-1 genes env, gag, and pol derived from the CRF01_AE strain predominant in Thailand. It was developed as part of heterologous prime-boost vaccination strategies for HIV prevention. The vaccine induces both cellular and humoral immune responses, with cell-mediated immunity predominantly involving HIV Env-specific CD4+ T cells and detectable binding antibodies against gp120 and p24. Clinical studies have shown that MVA-CMDR is safe, well-tolerated, immunogenic, and suitable for use as a boost in combination regimens with DNA-based priming vaccines[2][3][4][5].
- Other names
- MVA-CMDR Vaccine
02
Targets
Gag (HIV-1 Gag polyprotein)Pol (HIV-1 Pol polyprotein)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on MVA-CMDR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-CMDR.